目的 探讨百乐眠胶囊联合氟西汀和利培酮治疗抑郁症的临床疗效。方法 收集2015年5月-2016年3月在西安市长安医院接受治疗的抑郁症患者84例，根据治疗方案的差别分为对照组（42例）和治疗组（42例）。对照组口服盐酸氟西汀分散片，20 mg/次，1次/d；同时口服利培酮片，2 mg/次，1次/d。治疗组在对照基础上口服百乐眠胶囊，4粒/次，2次/d。两组患者均连续治疗4周。观察两组的临床疗效，同时比较两组患者治疗前后HAMD和WHOQOL-BREF评分变化情况。结果 治疗后，对照组与治疗组总有效率分别为80.95%和95.24%，两组间差异具有统计学意义（P<0.05）。治疗1、2、4周，两组HAMD评分均较同组治疗前显著降低，同组比较差异具有统计学意义（P<0.05）；治疗2、4周，治疗组的HAMD评分较对照组同期降低更显著，且差异具有统计学意义（P<0.05）。治疗后，两组患者生理健康、心理状态、社会关系和周围环境等WHOQOL-BREF评分较治疗前升高（P<0.05）；且治疗组WHOQOL-BREF评分比对照组的升高更明显，两组比较差异具有统计学意义（P<0.05）。结论 百乐眠胶囊联合氟西汀和利培酮治疗抑郁症疗效显著，可明显缓解患者忧郁状态，提高其生活质量，具有一定的临床推广应用价值。

Objective To observe the clinical effect of Bailemian Capsules combined with fluoxetine and risperidone in treatment of depression. Methods Patients (84 cases) with depression in Changan Hospital of Xi'an from May 2015 to March 2016 were enrolled in this study and divided into control (42 cases) and treatment (42 cases) groups according to different treatments. The patients in the control group were po administered with Fluoxetine Hydrochloride Dispersible Tablets, 20 mg/time, once daily. At the same time, the patients were po administered with Risperidone Tablets, 2 mg/time, once daily. The patients in the treatment group were po administered with Bailemian Capsules on the basis of the control group, 4 grains/time, twice daily. The patients in two groups were treated for 4 weeks. After treatment, clinical efficacy was evaluated, and the changes of HAMD and WHOQOL-BREF scores in two groups were compared before and after treatment. Results After treatment, the clinical effect in the control and treatment groups were 80.95% and 95.24%, respectively, and there was difference between two groups (P<0.05). After treatment for 1, 2, and 4 weeks, HAMD scores of two groups were obviously decreased, and the difference was statistically significant in the same group (P<0.05); After treatment for 2 and 4 weeks, HAMD scores of the treatment group decreased more obviously than those of the control group with significant difference (P<0.05). After treatment, the WHOQOL-BREF scores of physical health, psychological status, social relations, and surrounding environment in two groups were increased (P<0.05); And WHOQOL-BREF scores in the treatment group were higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Bailemian Capsules combined with fluoxetine and risperidone has a significant clinical effect in treatment of depression, can relieve the depression state, and improve the quality of life, which has a certain clinical application value.